EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus



Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus



Bone Marrow Transplantation 24(5): 517-520, Sept 1



Chronic graft-versus-host disease (GVHD) is a common late complication of allogeneic bone marrow transplantation (BMT) and is the principal cause of morbidity and non-relapse mortality. The improved management of acute GVHD has not translated into lower rates of chronic GVHD as older patients undergo allogeneic BMT, more patients receive unrelated or related mismatched allogeneic BMT, and donor lymphocyte infusion is increasingly used for treatment of post-BMT relapses. Patients with high risk chronic GVHD or those who fail on standard therapy have a bad prognosis. Salvage therapies have produced disappointing results. Here, we present a retrospective analysis of 26 patients where a steroid sparing synergistic combination of mycophenolate mofetil (MMF) and tacrolimus was used in refractory chronic GVHD. 46% patients showed an objective response, 11.5% had stable disease, 34.6% had progression and 7.7% were not evaluable. The combination was well tolerated. This promising preliminary result has prompted a trial to assess the safety and efficacy of this regimen in patients with chronic GVHD who have failed prior therapy and to determine if it would improve survival as well as quality of life in such patients.

Accession: 011323541

Download citation: RISBibTeXText

PMID: 10482936

DOI: 10.1038/sj.bmt.1701936



Related references

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 24(5): 517-520, 1999

Salvage therapy with mycophenolate mofetil and FK-506 for refractory chronic graft-versus-host disease. Blood 92(10 SUPPL 1 PART 1-2): 457A, Nov 15, 1998

Mycophenolate mofetil as salvage treatment for steroid-refractory chronic graft versus-host disease in children. Blood 98(11 Part 1): 398a, November 16, 2001

Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 88(7): 837-839, July, 2003

Mycophenolate mofetil as rescue therapy for high-risk steroid-refractory chronic graft versus-host-disease. Pediatric Research 53(4 Part 2): 275A, April, 2003

The use mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 92(10 SUPPL 1 PART 1-2): 346B, Nov 15, 1998

Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD). Haematologica 88(8): Elt28; Author Reply Elt29-Elt28; Author Reply Elt29, 2003

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84(10): 681-685, 2005

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83(1): 80-85, 2006

A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biology of Blood and Marrow Transplantation 16(7): 937-947, 2011

Benefits of mycophenolate mofetil for refractory graft-versus-host disease. Japanese Journal of Clinical Hematology 48(8): 624-631, 2007

Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 21(3): 496-502, 2015

Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 6(6): 613-620, 2000

Daclizumab +- mycophenolate mofetil for control of graft-versus-host disease in allogeneic stem cell transplant patients with cyclosporine or tacrolimus intolerance. Blood 98(11 Part 2): 353b, November 16, 2001

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biology of Blood and Marrow Transplantation 15(8): 919-929, 2009